 Design: This will be a multi-center, open-label, tissue-acquisition study involving 60 subjects from approximately 20 sites in North America and Europe, and will enroll EBC subjects of differing subtypes i.e., triple negative TNBC, ERHER2-, and HER2, with the intent of characterizing the molecular alterations in BC tissue before and after short-term exposure to the anti-androgen ODM-201. 